AbbVie Inc. (NYSE:ABBV) was upgraded by equities researchers at Leerink Swann from a “market perform” rating to an “outperform” rating in a report issued on Monday. The brokerage presently has a $106.00 price objective on the stock, up from their previous price objective of $89.00. Leerink Swann’s target price indicates a potential upside of 18.17% from the company’s previous close.

ABBV has been the topic of several other research reports. Credit Suisse Group reiterated a “hold” rating and issued a $65.00 price target on shares of AbbVie in a report on Wednesday, June 7th. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. Vetr lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $72.72 price objective for the company. in a report on Wednesday, June 14th. Societe Generale raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research cut shares of AbbVie from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $89.90.

AbbVie (NYSE ABBV) opened at 89.70 on Monday. The company’s 50 day moving average is $80.54 and its 200-day moving average is $71.50. The firm has a market cap of $142.99 billion, a P/E ratio of 22.06 and a beta of 1.51. AbbVie has a 52-week low of $55.06 and a 52-week high of $90.95. AbbVie also was the recipient of unusually large options trading on Monday. Stock investors acquired 278 put options on the company. This represents an increase of 121% compared to the typical daily volume of 126 put options.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm had revenue of $6.94 billion for the quarter, compared to analysts’ expectations of $6.93 billion. During the same period in the previous year, the firm earned $1.26 earnings per share. The business’s revenue was up 7.6% compared to the same quarter last year. On average, equities analysts predict that AbbVie will post $5.52 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/abbvie-inc-abbv-stock-rating-upgraded-by-leerink-swann.html.

In other news, Director Edward J. Rapp acquired 4,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were bought at an average cost of $70.45 per share, with a total value of $281,800.00. Following the transaction, the director now owns 15,498 shares of the company’s stock, valued at approximately $1,091,834.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Henry O. Gosebruch sold 18,000 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $70.09, for a total transaction of $1,261,620.00. Following the sale, the insider now directly owns 96,074 shares in the company, valued at $6,733,826.66. The disclosure for this sale can be found here. Insiders have sold 379,890 shares of company stock valued at $27,187,817 over the last 90 days. Corporate insiders own 0.23% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of AbbVie by 3.3% in the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock worth $8,405,409,000 after buying an additional 3,706,941 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of AbbVie by 1,949.7% during the second quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after buying an additional 3,646,510 shares during the last quarter. Orbis Allan Gray Ltd increased its position in shares of AbbVie by 35.7% during the second quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock valued at $921,233,000 after acquiring an additional 3,340,038 shares in the last quarter. Capital Research Global Investors increased its position in shares of AbbVie by 1.2% during the second quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock valued at $12,926,708,000 after acquiring an additional 2,130,919 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of AbbVie by 2.0% during the second quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock valued at $6,821,375,000 after acquiring an additional 1,864,418 shares in the last quarter. Institutional investors and hedge funds own 68.26% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.